Recombinant SARS-CoV-2 Spike S1 anticorps (RBD)

N° du produit ABIN6952546

Cet anticorps anti-SARS-CoV-2 Spike S1 est un anticorps Human Monoclonal détectant SARS-CoV-2 Spike S1 dans ELISA, IF, Crys et SPR. Adapté pour SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV), SARS CoV-2 Alpha, SARS CoV-2 Beta, SARS CoV-2 Epsilon, SARS CoV-2 Gamma, SARS CoV-2 Eta, SARS CoV-2 Kappa, SARS CoV-2 Delta et SARS CoV-2 Omicron. Validé indépendamment pour une utilisation dans Multiplex Immunohistochemistry. Ce Primary Antibody a été cité dans 8+ publications.

Aperçu rapide pour Recombinant SARS-CoV-2 Spike S1 anticorps (RBD) (ABIN6952546)

Antigène: SARS-CoV-2 Spike S1

Type d'anticorp: Recombinant Antibody

Reactivité: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV), SARS CoV-2 Alpha, SARS CoV-2 Beta, SARS CoV-2 Epsilon, SARS CoV-2 Gamma, SARS CoV-2 Eta, SARS CoV-2 Kappa, SARS CoV-2 Delta, SARS CoV-2 Omicron

Hôte: Human

Clonalité: Monoclonal

Conjugué: Cet anticorp SARS-CoV-2 Spike S1 est non-conjugé

Application: ELISA, Immunofluorescence (IF), Crystallization (Crys), Surface Plasmon Resonance (SPR)

Clone: CR3022

Détail du produit anti-SARS-CoV-2 Spike S1 anticorps

Highlights:

• Recombinant human neutralizing antibody (hNAb) against SARS-CoV-2.
• Binds SARS-CoV-2 S proteins of lineages B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.617.2 (delta), B.1.1.529 (omicron), B.1.429 (epsilon), B.1.525 (eta), and B.1.617.1 (kappa).
• Frequently used as reference in S-protein ELISAs and neutralization assays.
• Synergizes with other hNAbs: binds a highly conserved epitope, not interefering with the S-protein's ACE2 RBD.

Épitope: RBD

Fonction: Recombinant monoclonal antibody CR3022 to SARS-CoV S Glycoprotein.

Specificité:

The antibody CR3022 binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318-510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein (Joyce et al. 2020).

While most S-protein RBD binding antibodies compete for antigen binding with ACE2, the CR3022 epitope does not overlap with the ACE2-binding site. It does thus not hinder binding of neutralizing antibodies. While CR3022 on its own exhibits only a weak neutralizing effect, it has been shown to synergize with other S-protein RBD binding antibodies to neutralize SARS-CoV. This effect still has to be confirmed in context with SARS-CoV-2 (Yuan et al. 2020).

Réactivité croisée (Details): The anti-SARS-CoV-2 antibody CR3022 was originally discovered in a SARS patient, but it was shown to be a potent binder of SARS-CoV-2 spike protein (S1).

Attributs du produit:

Original Species of Ab: Human

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Immunogène: The original monoclonal antibody was generated through an scFv library derived from a peripheral blood lymphocytes of a patient exposed to the SARS-CoV.

Isotype: IgG1 kappa

Information d'application

Indications d'application: This antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 < a href="https://www.medrxiv.org/content/10.1101/2020.03.17.20037713v1" target="_blank">(Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-ompeting SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020). Bates et al. 2021 (PMID: 32766589) used CR3022 in a immunofluorescence assay.

Restrictions: For Research Use only

Independent Validation (mIHC)

Validation #104441 (Multiplex Immunohistochemistry)

by: Akoya Biosciences

No.: #104441

Date: 13.09.2022

Antigène: SARS-CoV-2 Spike S1

Numéro du lot: T2023B03

Application validée: Multiplex Immunohistochemistry

Contrôle positif:

FFPE cell pellets from in vitro cultured human lung cells infected with SARS-CoV-2

Contrôle négative:

SARS-CoV-2-negative placenta patient sample

Conclusion:

Passed. The anti-SARS-CoV-2 Spike S1 antibody RBD antibody ABIN6952546 produced staining in FFPE cell pellets from in vitro cultured human lung cells infected with SARS-CoV-2.

Validation Images

Immunofluorescence of SARS-CoV-2 infection in FFPE cell pellets from in vitro cultured human lung cells infected with SARS-CoV-2. Anti-SARS-CoV-2 Spike S1 antibody RBD antibody ABIN6952546 is visualized with PhenoCycler reporters in green and DAPI-stained chromatin in blue.

Immunofluorescence of SARS-CoV-2 infection in FFPE cell pellets from in vitro cultured human lung cells infected with SARS-CoV-2. Costaining with anti-SARS-CoV-2 Spike S1 antibody RBD antibody ABIN6952546 (green) and anti-SARS-CoV-2 Nucleocapsid Protein antibody ABIN6952544 (red).

Protocole

Anticorps primaire: ABIN6952546

Full Protocol:

• Protocol details are described in the Akoya Biosciences CODEX® User Manual (see https://www.akoyabio.com/wp-content/uploads/2021/01/CODEX-User-Manual.pdf).
• Tissue preparation as outlined in the Akoya Biosciences CODEX® User Manual FFPE tissue protocol.
• Conjugation of the anti-SARS-CoV-2 Spike S1 antibody RBD antibody ABIN6952546 as described in Chapter 4 of the Akoya Biosciences CODEX® User Manual.
• Autofluorescence quenching according to the Autofluorescence Quenching Protocol for CODEX® (see https://www.akoyabio.com/wp-content/uploads/2020/07/Customer-Demonstrated-Protocol-Autofluorescence-Quenching-Mar2020.pdf).

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Références pour anticorps anti-SARS-CoV-2 Spike S1 (ABIN6952546)

Kannenberg, Trawinski, Henschler, Buhmann, Hönemann, Jassoy: "Antibody course and memory B-cell response in the first year after SARS-CoV-2 infection." dans: The Journal of infectious diseases, (2022) (PubMed).

Jacobsen, Fabricius, Class, Topfstedt, Lorenzetti, Janowska, Schmidt, Staniek, Zernickel, Stamminger, Dietz, Zellmer, Hecht, Rauch, Blum, Ludwig, Jahrsdörfer, Schrezenmeier, Heeg, Mayer, Seidel, Groß et al.: "High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection. ..." dans: Nature communications, Vol. 13, Issue 1, pp. 7315, (2022) (PubMed).

Hennrich, Sawatsky, Santos-Mandujano, Banda, Oberhuber, Schopf, Pfaffinger, Wittwer, Riedel, Pfaller, Conzelmann: "Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization." dans: PLoS pathogens, Vol. 17, Issue 4, pp. e1009064, (2021) (PubMed).

Tian, Li, Huang, Xia, Lu, Shi, Lu, Jiang, Yang, Wu, Ying: "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody." dans: Emerging microbes & infections, Vol. 9, Issue 1, pp. 382-385, (2020) (PubMed).

Stadlbauer, Amanat, Chromikova, Jiang, Strohmeier, Arunkumar, Tan, Bhavsar, Capuano, Kirkpatrick, Meade, Brito, Teo, McMahon, Simon, Krammer: "SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup." dans: Current protocols in microbiology, Vol. 57, Issue 1, pp. e100, (2020) (PubMed).

Yuan, Wu, Zhu, Lee, So, Lv, Mok, Wilson: "A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV." dans: Science (New York, N.Y.), (2020) (PubMed).

Pinto, Park, Beltramello, Walls, Tortorici, Bianchi, Jaconi, Culap, Zatta, De Marco, Peter, Guarino, Spreafico, Cameroni, Case, Chen, Havenar-Daughton, Snell, Telenti, Virgin, Lanzavecchia, Diamond et al.: "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody." dans: Nature, (2020) (PubMed).

ter Meulen, van den Brink, Poon, Marissen, Leung, Cox, Cheung, Bakker, Bogaards, van Deventer, Preiser, Doerr, Chow, de Kruif, Peiris, Goudsmit: "Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants." dans: PLoS medicine, Vol. 3, Issue 7, pp. e237, (2007) (PubMed).

Détails sur SARS-CoV-2 Spike S1

Antigène: SARS-CoV-2 Spike S1

Classe de substances: Viral Protein

Sujet: Spike protein, COVID19, COVID 19, S protein, SARS-CoV S protein, S glycoprotein, E2, Peplomer protein, Spike protein S1, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV, Ab1680.10, Ab1680.15, Ab1680.16

UniProt: P59594